Tags

Type your tag names separated by a space and hit enter

New world cutaneous leishmaniasis in travellers.
Lancet Infect Dis. 2006 Jun; 6(6):342-9.LI

Abstract

As travel to Latin America has become increasingly common, cutaneous leishmaniasis is increasingly seen among returning travellers--eg, the number of observed cases has doubled in the Netherlands and tripled in the UK in the past decade. A surprisingly high proportion of cases were acquired in rural or jungle areas of the Amazon basin in Bolivia. The clinical manifestations range from ulcerative skin lesions (cutaneous leishmaniasis) to a destructive mucosal inflammation (mucocutaneous leishmaniasis), the latter usually being a complication of infection with Leishmania (Viannia) braziliensis. PCR is now the diagnostic method of choice, since it has a high sensitivity and gives a species-specific diagnosis, allowing species-specific treatment. Treatment of cutaneous leishmaniasis aims to prevent mucosal invasion, to accelerate the healing of the skin lesion(s), and to avoid disfiguring scars. Pentavalent antimonials drugs are still the drug of choice for many patients. However, a high rate of adverse events, length of treatment, and relapses in up to 25% of cases highlight the limitations of these drugs. Although only used in a small number of patients thus far, liposomal amphotericin B shows promising results. Further studies are needed to find efficacious and better-tolerated drugs for new world leishmaniasis.

Authors+Show Affiliations

The Center for Geographic Medicine and Tropical Diseases, Chaim Sheba Medical Center, Sackler School of Medicine, Tel Aviv University, Israel. elischwa@post.tau.ac.ilNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

16728320

Citation

Schwartz, Eli, et al. "New World Cutaneous Leishmaniasis in Travellers." The Lancet. Infectious Diseases, vol. 6, no. 6, 2006, pp. 342-9.
Schwartz E, Hatz C, Blum J. New world cutaneous leishmaniasis in travellers. Lancet Infect Dis. 2006;6(6):342-9.
Schwartz, E., Hatz, C., & Blum, J. (2006). New world cutaneous leishmaniasis in travellers. The Lancet. Infectious Diseases, 6(6), 342-9.
Schwartz E, Hatz C, Blum J. New World Cutaneous Leishmaniasis in Travellers. Lancet Infect Dis. 2006;6(6):342-9. PubMed PMID: 16728320.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - New world cutaneous leishmaniasis in travellers. AU - Schwartz,Eli, AU - Hatz,Cristoph, AU - Blum,Johannes, PY - 2006/5/27/pubmed PY - 2006/6/24/medline PY - 2006/5/27/entrez SP - 342 EP - 9 JF - The Lancet. Infectious diseases JO - Lancet Infect Dis VL - 6 IS - 6 N2 - As travel to Latin America has become increasingly common, cutaneous leishmaniasis is increasingly seen among returning travellers--eg, the number of observed cases has doubled in the Netherlands and tripled in the UK in the past decade. A surprisingly high proportion of cases were acquired in rural or jungle areas of the Amazon basin in Bolivia. The clinical manifestations range from ulcerative skin lesions (cutaneous leishmaniasis) to a destructive mucosal inflammation (mucocutaneous leishmaniasis), the latter usually being a complication of infection with Leishmania (Viannia) braziliensis. PCR is now the diagnostic method of choice, since it has a high sensitivity and gives a species-specific diagnosis, allowing species-specific treatment. Treatment of cutaneous leishmaniasis aims to prevent mucosal invasion, to accelerate the healing of the skin lesion(s), and to avoid disfiguring scars. Pentavalent antimonials drugs are still the drug of choice for many patients. However, a high rate of adverse events, length of treatment, and relapses in up to 25% of cases highlight the limitations of these drugs. Although only used in a small number of patients thus far, liposomal amphotericin B shows promising results. Further studies are needed to find efficacious and better-tolerated drugs for new world leishmaniasis. SN - 1473-3099 UR - https://www.unboundmedicine.com/medline/citation/16728320/New_world_cutaneous_leishmaniasis_in_travellers_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1473-3099(06)70492-3 DB - PRIME DP - Unbound Medicine ER -